Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 563 entries
View as:

A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

Phase: N/A Priority: Normal
NCT ID: NCT02046694 Org: User:
Start: 01/06/14 End: 04/06/20 Due: 04/06/21

Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens

Phase: N/A Priority: Normal
NCT ID: NCT00681993 Org: User:
Start: 04/30/08 End: 03/04/16 Due: 03/04/17

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT04753879 Org: User:
Start: 09/29/21 End: 12/01/29 Due: 12/01/30

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02489357 Org: User:
Start: 12/11/15 End: 11/30/17 Due: 11/30/18

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00005639 Org: User:
Start: 03/31/00 End: 07/31/05 Due: 07/31/06

Observation of Perioperative Outcomes of Robotic Pancreaticoduodenectomy

Phase: N/A Priority: Normal
NCT ID: NCT04171440 Org: User:
Start: 02/18/20 End: 08/31/25 Due: 08/31/26

Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

Phase: N/A Priority: Normal
NCT ID: NCT02864316 Org: User:
Start: 12/31/16 End: 09/30/18 Due: 09/30/19

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03413995 Org: User:
Start: 09/10/18 End: 09/12/24 Due: 09/12/25

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00390364 Org: User:
Start: 10/31/06 End: 10/31/07 Due: 10/31/08

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01861340 Org: User:
Start: 05/31/14 End: 07/31/16 Due: 07/31/17

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Phase: N/A Priority: Normal
NCT ID: NCT02090114 Org: User:
Start: 08/25/14 End: 11/11/21 Due: 11/11/22

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04037358 Org: User:
Start: 08/09/19 End: 12/31/28 Due: 12/31/29

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02981524 Org: User:
Start: 05/26/17 End: 03/20/18 Due: 03/20/19

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Phase: N/A Priority: Normal
NCT ID: NCT01349569 Org: User:
Start: 01/31/12 End: 10/31/16 Due: 10/31/17

Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00002778 Org: User:
Start: 02/28/95 End: 07/31/10 Due: 07/31/11

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT02702960 Org: User:
Start: 03/31/16 End: 01/03/18 Due: 01/03/19

Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00293410 Org: User:
Start: 11/30/05 End: - Due: -

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05014776 Org: User:
Start: 08/22/22 End: 04/03/26 Due: 04/03/27

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

Phase: N/A Priority: Normal
NCT ID: NCT04848116 Org: User:
Start: 04/24/21 End: 09/30/26 Due: 09/30/27

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Phase: N/A Priority: Normal
NCT ID: NCT01750398 Org: User:
Start: 01/31/13 End: 06/30/15 Due: 06/30/16

Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00095589 Org: User:
Start: 08/31/04 End: 06/30/09 Due: 06/30/10

MRI for Assessing Prostate Cancer Response

Phase: N/A Priority: Normal
NCT ID: NCT01607008 Org: User:
Start: 11/16/12 End: 12/31/27 Due: 12/31/28

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase: N/A Priority: Normal
NCT ID: NCT06564623 Org: User:
Start: 05/27/25 End: 05/31/29 Due: 05/31/30

Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT02177578 Org: User:
Start: 07/08/14 End: 12/31/32 Due: 12/31/33

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Phase: N/A Priority: Normal
NCT ID: NCT05977907 Org: User:
Start: 12/14/23 End: 10/16/28 Due: 10/16/29